How to Price an Assessment: The Signal, the Ladder, and the One-Third Test

Before a prospect reads a single question of your assessment, they have already read one piece of it: the price. And from that one number, they've drawn a complete set of conclusions about how serious it is, how deep it goes, and whether it deserves a slot on their calendar.

This is the part most founders of expertise businesses get backwards. They obsess over the instrument — the dimensions, the scoring model, the report design — and then attach a number almost as an afterthought. Usually a low one, on the theory that a modest price lowers the barrier to entry.

It does the opposite. In a market where the buyer cannot inspect quality before purchasing, a low price doesn't read as accessible. It reads as shallow.

Hermann Simon lays out the mechanism in Confessions of the Pricing Man: when buyers have no direct way to evaluate quality, the price itself becomes the quality signal. Professional services are the purest case of this — the work is invisible until after the money has changed hands. Which means your diagnostic's price isn't just what you charge. It's the first claim you make about what the diagnostic is.

Price Is the Only Spec Sheet Your Buyer Can Read

What $500, $5,000, and $25,000 Each Claim About Your Work

A buyer evaluating a car can take a test drive. A buyer evaluating software can start a trial. A buyer evaluating your assessment can do neither — the entire value is locked inside an experience they haven't had yet. So they reach for the one data point that's available before purchase, and they treat it as a specification.

At $500, the specification reads: automated. A self-serve quiz, probably built in an afternoon, producing the kind of output the buyer suspects they could have assembled themselves with a form tool and a spreadsheet. Accuracy is irrelevant here — the categorization happens before anyone verifies it.

At $5,000, the same instrument reads as methodology. There's a real framework behind this. The output will be substantial enough to put in front of a leadership team. Buying it is a decision, not an impulse — which is exactly what makes the buyer take it seriously.

At $25,000, the price claims enterprise-grade: proprietary benchmarking, board-ready output, analysis deep enough to justify executive attention and inform real resource decisions.

I watched a consultant I advise live through this exact mechanic. Eight months of design work — weighted scoring, structured dimensions, benchmarking built from a decade of client engagements — launched at $750. Sales: none. The instrument wasn't the problem; the number was telling prospects it was a glorified questionnaire. She relaunched the identical diagnostic at $5,000, wrapped in a 90-minute guided session and a benchmarked report, and sold twelve in the first quarter. The assessment never changed. The signal did.

Harry Beckwith gives the underlying principle a memorable form in Selling the Invisible: "Charge by the years, not by the hour." The diagnostic took her ninety minutes to deliver and ten years to be able to build. The fee should answer to the second number, not the first.

The Diagnosis Is the Product — Stop Handing It Out

Why a Free Assessment Costs More Than It Earns

Before we get to tier structure, deal with the most common pricing failure first — because it happens before any price is even quoted. A prospect asks to see the full assessment results before committing to anything bigger. It sounds like a fair request, and saying yes feels like relationship-building. So the founder runs the diagnostic free, banking on the larger engagement that will surely follow.

Blair Enns wrote The Win Without Pitching Manifesto partly to kill this reflex: "Under no circumstances will we part with our thinking without appropriate compensation." Ron Baker frames the cost differently — give the diagnostic away and you've commoditized the single highest-value step in your methodology.

In practice, the free diagnostic resolves in one of three ways, none of them the engagement you were hoping for:

• The findings get implemented in-house. Armed with your diagnosis, the prospect concludes they can handle the treatment themselves — or believes they can, which has the same effect on your pipeline.
• Your analysis becomes their shopping list. The clarity you produced gets handed to cheaper providers who could never have generated it, but can execute against it once it exists.
• Free becomes the precedent. Every subsequent conversation now starts from the assumption that your thinking arrives before your invoice does. That power shift doesn't reverse.

None of this argues against a free entry point — it argues for designing one deliberately. Simon's work on freemium draws the line cleanly: the free version must be genuinely useful and visibly incomplete. A single dimension scored, no benchmarks, no recommendations. It should produce an "aha," and then a question the buyer can't answer without paying. Interesting, but not sufficient.

Hold the line because of what the diagnostic actually is: the moment in the whole relationship where invisible problems become visible and vague unease becomes a quantified gap. The buyers who recognize that moment is worth paying for are your market. The ones who want it free were never going to fund the work that follows it.

Build the Ladder: Three Tiers, Quoted Top-Down

Snapshot, Benchmark, Mandate — and Why You Lead with the Biggest Number

Combine Simon's pricing research with Alan Weiss's value-based fee work and a natural three-rung structure emerges for diagnostics. Each rung is a different promise, sold to a different buyer:

The Snapshot ($1,000-$3,000). This buyer wants to know where they stand. A score, a clear professional report, something citable in an internal deck. Typical buyers: small business owners, individual contributors, mid-level managers spending departmental budget. Delivery stays lean — roughly a 60-minute guided session and a standardized report. Useful, credible, deliberately not strategic.

The Benchmark ($5,000-$15,000). This buyer wants to know what the score means. How do they compare against peers? Where are the gaps, and which ones matter first? Output expands to benchmarking, gap analysis, and prioritized recommendations, usually delivered through a guided session plus a follow-up presentation. Buyers here are VPs, senior managers, and department heads with strategic budgets — and this tier is where deeper client relationships tend to begin.

The Mandate ($15,000-$50,000). This buyer is funding a transformation, and the diagnostic is phase one of it. Multi-stakeholder assessment, cross-organizational benchmarking, executive-ready presentations, and a roadmap with milestones and resource requirements. Engagements run multiple weeks, with interviews and parallel data collection. The audience is the C-suite, board members, and transformation leads — people whose capital-allocation decisions your findings will directly shape.

Now the presentation rule, and it's non-negotiable: quote from the top of the ladder down. Weiss insists on it, and Simon's anchoring research explains why it works — whatever number the buyer hears first becomes the yardstick for every number after it. Open at $25,000 and a $7,500 option lands as reasonable. Open at $2,000 and that same $7,500 sounds inflated.

Put all three rungs into every sales conversation. The buyer who sees one price decides yes or no. The buyer who sees three decides which — and "which" is a conversation you win far more often.

Calibrate with the One-Third Test

If Nobody Walks Away, Your Price Is Wrong

How do you know the numbers on your ladder are right? Ron Baker supplies the cleanest calibration I know of: when your diagnostic is priced correctly, about one in three prospects should turn it down on price.

Most founders flinch at that. Deliberately pricing so that a third of interested buyers walk away sounds like setting revenue on fire.

Read the failure modes on either side and the logic snaps into place. A rejection rate near zero means every prospect finds your fee easy to swallow — which means you're underpriced, leaving money behind, and broadcasting a price signal that undercuts the premium quality you're claiming. Everyone-says-yes is not a win condition; it's a symptom.

On the other side, if rejections climb past 60%, one of two things is true. Either the fee genuinely exceeds what the market will bear, or — far more often — your positioning hasn't built the perceived value to support it. The instrument may be excellent; the market hasn't been shown why. The corrective is almost never a discount. It's better positioning.

At roughly one-third, the rejections stop being losses and start being a filter. Demand at the current price is healthy enough that walk-aways don't sting, and the buyers who proceed anyway — eyes open, full price — show up more committed, engage more seriously, and convert into follow-on work at higher rates.

Make this a measured number, not a feeling. Log every diagnostic sales conversation, mark whether price resistance surfaced, and compute the rate monthly. Move your price when the data says move it. Fear doesn't get a vote.